Literature DB >> 14670133

Concentrations and ratios of amphetamine, methamphetamine, MDA, MDMA, and MDEA enantiomers determined in plasma samples from clinical toxicology and driving under the influence of drugs cases by GC-NICI-MS.

F T Peters1, N Samyn, M Wahl, T Kraemer, G De Boeck, H H Maurer.   

Abstract

Enantiomers of amphetamine (AM), methamphetamine (MA), 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine (MDMA), and 3,4-methylenedioxyethylamphetamine (MDEA) exhibit different pharmacological properties. This may be important for the interpretation of analytical results. Plasma samples were analyzed using validated negative ion chemical ionization gas chromatography-mass spectrometry procedures. The results for clinical toxicology cases, divided into screening (SCR) and intoxication (ITX) cases, and those of driving under the influence of drugs (DUID) cases were compared. The concentrations of all enantiomers, except R-(-)-MDA and R-(-)- and S-(+)-MA, in the SCR samples were lower than in ITX and DUID samples. Differences between concentrations in ITX and DUID samples were only significant for both enantiomers of AM (DUID higher). These findings suggested impairment in drugged drivers. Different enantiomer ratios (R vs. S) were found for AM between DUID and SCR samples, for MDMA between ITX and SCR samples, and for MDA between DUID and ITX and DUID and SCR samples. Higher MDMA enantiomer ratios in SCR compared to ITX samples are in accordance with a previously described increase of those ratios over time, possibly allowing differentiation of recent from nonrecent ingestion. Pharmacokinetic analysis of a MDMA poisoning yielded elimination half-lives of 6.0 h for R-(-)-MDMA and 4.1 h for S-(+)-MDMA. The enantiomer ratios rose exponentially over time.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14670133     DOI: 10.1093/jat/27.8.552

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  8 in total

1.  Rapid quantitative chiral amphetamines liquid chromatography-tandem mass spectrometry: method in plasma and oral fluid with a cost-effective chiral derivatizing reagent.

Authors:  Matthew N Newmeyer; Marta Concheiro; Marilyn A Huestis
Journal:  J Chromatogr A       Date:  2014-07-05       Impact factor: 4.759

2.  Stereoselective urinary MDMA (ecstasy) and metabolites excretion kinetics following controlled MDMA administration to humans.

Authors:  Andrea E Schwaninger; Markus R Meyer; Allan J Barnes; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis; Hans H Maurer
Journal:  Biochem Pharmacol       Date:  2011-09-29       Impact factor: 5.858

Review 3.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors:  J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2010-11-04       Impact factor: 2.007

4.  Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urine.

Authors:  Andrea E Schwaninger; Markus R Meyer; Marilyn A Huestis; Hans H Maurer
Journal:  J Mass Spectrom       Date:  2011-07       Impact factor: 1.982

Review 5.  Trace amine-associated receptors as emerging therapeutic targets.

Authors:  Tatyana D Sotnikova; Marc G Caron; Raul R Gainetdinov
Journal:  Mol Pharmacol       Date:  2009-04-23       Impact factor: 4.436

Review 6.  Trace amine-associated receptor 1-Family archetype or iconoclast?

Authors:  David K Grandy
Journal:  Pharmacol Ther       Date:  2007-07-17       Impact factor: 12.310

7.  A validated gas chromatographic-electron impact ionization mass spectrometric method for methamphetamine, methylenedioxymethamphetamine (MDMA), and metabolites in mouse plasma and brain.

Authors:  Karl B Scheidweiler; Allan J Barnes; Marilyn A Huestis
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-11-07       Impact factor: 3.205

8.  Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.

Authors:  Andrea E Steuer; Corina Schmidhauser; Eva H Tingelhoff; Yasmin Schmid; Anna Rickli; Thomas Kraemer; Matthias E Liechti
Journal:  PLoS One       Date:  2016-03-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.